| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
29,853 |
28,248 |
$2.03M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
8,208 |
8,153 |
$528K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,823 |
5,602 |
$298K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,005 |
1,000 |
$99K |
| 81025 |
|
10,366 |
10,059 |
$61K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
7,680 |
7,324 |
$56K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,323 |
2,297 |
$26K |
| 99058 |
|
2,363 |
2,232 |
$23K |
| 81002 |
|
8,529 |
8,326 |
$20K |
| 99441 |
|
721 |
671 |
$15K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
168 |
168 |
$10K |
| 99215 |
Prolong outpt/office vis |
122 |
121 |
$9K |
| 99000 |
|
1,307 |
1,266 |
$8K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
664 |
651 |
$7K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
442 |
259 |
$5K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,003 |
971 |
$4K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,778 |
2,650 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
168 |
168 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
106 |
102 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,634 |
4,531 |
$3K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
31 |
31 |
$1K |
| 73120 |
|
28 |
27 |
$310.41 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
13 |
13 |
$220.32 |
| 36415 |
Collection of venous blood by venipuncture |
58 |
56 |
$132.30 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
13 |
13 |
$90.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
71 |
68 |
$19.92 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
43 |
40 |
$14.32 |
| 99072 |
|
4,553 |
4,303 |
$7.00 |
| G8732 |
No documentation of pain assessment, reason not given |
13 |
13 |
$0.00 |
| 1000F |
|
55 |
55 |
$0.00 |
| 3074F |
|
39 |
39 |
$0.00 |
| 1036F |
|
15 |
15 |
$0.00 |
| 1034F |
|
13 |
13 |
$0.00 |
| 3079F |
|
15 |
15 |
$0.00 |
| 3078F |
|
19 |
19 |
$0.00 |
| 1033F |
|
13 |
13 |
$0.00 |
| 4040F |
|
19 |
19 |
$0.00 |
| 4025F |
|
30 |
30 |
$0.00 |
| G8484 |
Influenza immunization was not administered, reason not given |
12 |
12 |
$0.00 |